Center-Authored Papers

Filters: Author is Kahl, Brad S  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
B
Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM et al..  2015.  Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
C
Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA et al..  2016.  RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.. British journal of haematology. Abstract
G
Gopal AK, Kahl BS, Flowers CR, Martin P, Ansell SM, Abella-Dominicis E, Koh B, Ye W, Barr PM, Salles GA et al..  2017.  Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.. Blood.
Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A et al..  2014.  PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma.. The New England journal of medicine. Abstract
H
Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA et al..  2016.  A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.. Cancer. Abstract
Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, Federico M, Gisselbrecht C, Schwartz M, Bellm LA et al..  2017.  Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States.. Clinical lymphoma, myeloma & leukemia. Abstract
N
Nowakowski GS, Blum KA, Kahl BS, Friedberg JW, Baizer L, Little RF, Maloney DG, Sehn LH, Williams ME, Wilson WH et al..  2016.  Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.. Journal of the National Cancer Institute. 108(12) Abstract
P
Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES et al..  2016.  US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(17):2020-+. Abstract
S
Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA, Flowers CR, Jurczak WJ, Flinn IW, Kahl BS et al..  2016.  Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.. Haematologica.
Spurgeon SE, Till BG, Martin P, Goy AH, Dreyling MP, Gopal AK, LeBlanc M, Leonard JP, Friedberg JW, Baizer L et al..  2017.  Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.. Journal of the National Cancer Institute. 109(1) Abstract
Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS et al..  2013.  Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.. The New England journal of medicine. 369(18):1681-90. Abstract
W
Williams ME, Connors JM, Dreyling MH, Gascoyne RD, Kahl BS, Leonard JP, Press OW, Wilson WH.  2011.  Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop.. Leukemia & lymphoma. 52(1):24-33. Abstract